HSP70 variations in the acute treatment with mood stabilizers in patients with bipolar disorder

Results of a preliminary work

Chi Un Pae, Antonio Drago, Jung Jin Kim, Laura Mandelli, Ashwin A. Patkar, Diana de Ronchi, Alessandro Serretti

Research output: Contribution to journalArticle

Abstract

A pharmacogenetic approach was used to investigate the role of heat shock protein (HSP) 70 on the effect of mood stabilizers since a line of evidence has proposed a possible involvement of its chaperone activity in the pathophysiology of bipolar disorders. Forty five patients with bipolar I disorder were treated for an average of 36.5 (±19.9) days with mood stabilizers (lithium, valproate, or carbamazepine), were evaluated with using the Clinical Global Impression (CGI) scale and the Young Mania Rating Scale (YMRS), and were genotyped for their HSP 70 variants (rs2227956 C/T, rs2075799 A/G, rs1043618 C/G, rs562047 C/G, rs539689 C/G). Results: No association was found between the investigated variations and response to mood stabilizer treatments even considering possible stratification factors. The small number of subjects is an important limitation to the present study, nonetheless HSP 70 gene variants seem not to be involved in acute antimanic effect. Adequately-powered study would properly address the potential role of HSP 70 gene variants for the effect of mood stabilizers.

Original languageEnglish
Pages (from-to)267-276
Number of pages10
JournalGene Therapy and Molecular Biology
Volume12
Issue number2
Publication statusPublished - 2008

Fingerprint

HSP70 Heat-Shock Proteins
Bipolar Disorder
Antimanic Agents
Pharmacogenetics
Carbamazepine
Valproic Acid
Therapeutics
Lithium
Genes

Keywords

  • Bipolar disorder
  • Heat shock proteins
  • Lithium
  • Manic
  • Pharmacogenetics

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine

Cite this

Pae, C. U., Drago, A., Kim, J. J., Mandelli, L., Patkar, A. A., de Ronchi, D., & Serretti, A. (2008). HSP70 variations in the acute treatment with mood stabilizers in patients with bipolar disorder: Results of a preliminary work. Gene Therapy and Molecular Biology, 12(2), 267-276.

HSP70 variations in the acute treatment with mood stabilizers in patients with bipolar disorder : Results of a preliminary work. / Pae, Chi Un; Drago, Antonio; Kim, Jung Jin; Mandelli, Laura; Patkar, Ashwin A.; de Ronchi, Diana; Serretti, Alessandro.

In: Gene Therapy and Molecular Biology, Vol. 12, No. 2, 2008, p. 267-276.

Research output: Contribution to journalArticle

Pae, CU, Drago, A, Kim, JJ, Mandelli, L, Patkar, AA, de Ronchi, D & Serretti, A 2008, 'HSP70 variations in the acute treatment with mood stabilizers in patients with bipolar disorder: Results of a preliminary work', Gene Therapy and Molecular Biology, vol. 12, no. 2, pp. 267-276.
Pae, Chi Un ; Drago, Antonio ; Kim, Jung Jin ; Mandelli, Laura ; Patkar, Ashwin A. ; de Ronchi, Diana ; Serretti, Alessandro. / HSP70 variations in the acute treatment with mood stabilizers in patients with bipolar disorder : Results of a preliminary work. In: Gene Therapy and Molecular Biology. 2008 ; Vol. 12, No. 2. pp. 267-276.
@article{64f91183485d4c54acc9824556f83c4c,
title = "HSP70 variations in the acute treatment with mood stabilizers in patients with bipolar disorder: Results of a preliminary work",
abstract = "A pharmacogenetic approach was used to investigate the role of heat shock protein (HSP) 70 on the effect of mood stabilizers since a line of evidence has proposed a possible involvement of its chaperone activity in the pathophysiology of bipolar disorders. Forty five patients with bipolar I disorder were treated for an average of 36.5 (±19.9) days with mood stabilizers (lithium, valproate, or carbamazepine), were evaluated with using the Clinical Global Impression (CGI) scale and the Young Mania Rating Scale (YMRS), and were genotyped for their HSP 70 variants (rs2227956 C/T, rs2075799 A/G, rs1043618 C/G, rs562047 C/G, rs539689 C/G). Results: No association was found between the investigated variations and response to mood stabilizer treatments even considering possible stratification factors. The small number of subjects is an important limitation to the present study, nonetheless HSP 70 gene variants seem not to be involved in acute antimanic effect. Adequately-powered study would properly address the potential role of HSP 70 gene variants for the effect of mood stabilizers.",
keywords = "Bipolar disorder, Heat shock proteins, Lithium, Manic, Pharmacogenetics",
author = "Pae, {Chi Un} and Antonio Drago and Kim, {Jung Jin} and Laura Mandelli and Patkar, {Ashwin A.} and {de Ronchi}, Diana and Alessandro Serretti",
year = "2008",
language = "English",
volume = "12",
pages = "267--276",
journal = "Gene Therapy and Molecular Biology",
issn = "1529-9120",
publisher = "Gene Therapy and Molecular Biology",
number = "2",

}

TY - JOUR

T1 - HSP70 variations in the acute treatment with mood stabilizers in patients with bipolar disorder

T2 - Results of a preliminary work

AU - Pae, Chi Un

AU - Drago, Antonio

AU - Kim, Jung Jin

AU - Mandelli, Laura

AU - Patkar, Ashwin A.

AU - de Ronchi, Diana

AU - Serretti, Alessandro

PY - 2008

Y1 - 2008

N2 - A pharmacogenetic approach was used to investigate the role of heat shock protein (HSP) 70 on the effect of mood stabilizers since a line of evidence has proposed a possible involvement of its chaperone activity in the pathophysiology of bipolar disorders. Forty five patients with bipolar I disorder were treated for an average of 36.5 (±19.9) days with mood stabilizers (lithium, valproate, or carbamazepine), were evaluated with using the Clinical Global Impression (CGI) scale and the Young Mania Rating Scale (YMRS), and were genotyped for their HSP 70 variants (rs2227956 C/T, rs2075799 A/G, rs1043618 C/G, rs562047 C/G, rs539689 C/G). Results: No association was found between the investigated variations and response to mood stabilizer treatments even considering possible stratification factors. The small number of subjects is an important limitation to the present study, nonetheless HSP 70 gene variants seem not to be involved in acute antimanic effect. Adequately-powered study would properly address the potential role of HSP 70 gene variants for the effect of mood stabilizers.

AB - A pharmacogenetic approach was used to investigate the role of heat shock protein (HSP) 70 on the effect of mood stabilizers since a line of evidence has proposed a possible involvement of its chaperone activity in the pathophysiology of bipolar disorders. Forty five patients with bipolar I disorder were treated for an average of 36.5 (±19.9) days with mood stabilizers (lithium, valproate, or carbamazepine), were evaluated with using the Clinical Global Impression (CGI) scale and the Young Mania Rating Scale (YMRS), and were genotyped for their HSP 70 variants (rs2227956 C/T, rs2075799 A/G, rs1043618 C/G, rs562047 C/G, rs539689 C/G). Results: No association was found between the investigated variations and response to mood stabilizer treatments even considering possible stratification factors. The small number of subjects is an important limitation to the present study, nonetheless HSP 70 gene variants seem not to be involved in acute antimanic effect. Adequately-powered study would properly address the potential role of HSP 70 gene variants for the effect of mood stabilizers.

KW - Bipolar disorder

KW - Heat shock proteins

KW - Lithium

KW - Manic

KW - Pharmacogenetics

UR - http://www.scopus.com/inward/record.url?scp=77649158361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649158361&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 267

EP - 276

JO - Gene Therapy and Molecular Biology

JF - Gene Therapy and Molecular Biology

SN - 1529-9120

IS - 2

ER -